On November 1, The University of Pennsylvania launched a new partnership with Johnson & Johnson Innovation, the health care giant’s collaborative arm. Known as JPOD @ Philadelphia and based in the Pennovation Center, JPOD is a start-up incubator designed to accelerate innovative health care technologies.  Among the several companies there is Prohibix, a company started by CEMB researcher Jason Burdick, Robert D. Bent Professor in Bioengineering.  Prohibix is an early stage company developing injectable therapeutics that locally prevent the progression of tissue degenerative diseases and preserve quality of life. Spun-out of research by  Dr. Burdick,  Prohibix’s hydrogel-based drug delivery technology aims to target a critical mediator of many diseases including cardiovascular disease, osteoarthritis, and chronic ulcers.